SI1047665T1 - Inhibitorji matriks-metaloproteaze - Google Patents

Inhibitorji matriks-metaloproteaze

Info

Publication number
SI1047665T1
SI1047665T1 SI9830577T SI9830577T SI1047665T1 SI 1047665 T1 SI1047665 T1 SI 1047665T1 SI 9830577 T SI9830577 T SI 9830577T SI 9830577 T SI9830577 T SI 9830577T SI 1047665 T1 SI1047665 T1 SI 1047665T1
Authority
SI
Slovenia
Prior art keywords
matrix metalloprotease
metalloprotease inhibitors
inhibitors
matrix
metalloprotease
Prior art date
Application number
SI9830577T
Other languages
English (en)
Inventor
Michael Jonathan Fray
Roger Peter Dickinson
Kevin Neil Dack
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800510.1A external-priority patent/GB9800510D0/en
Priority claimed from GBGB9811843.3A external-priority patent/GB9811843D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of SI1047665T1 publication Critical patent/SI1047665T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI9830577T 1998-01-09 1998-12-23 Inhibitorji matriks-metaloproteaze SI1047665T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9800510.1A GB9800510D0 (en) 1998-01-09 1998-01-09 Therapeutic agents
GBGB9811843.3A GB9811843D0 (en) 1998-06-02 1998-06-02 Therapeutic agents
PCT/EP1998/008565 WO1999035124A1 (en) 1998-01-09 1998-12-23 Matrix metalloprotease inhibitors
EP98966429A EP1047665B1 (en) 1998-01-09 1998-12-23 Matrix metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
SI1047665T1 true SI1047665T1 (sl) 2004-02-29

Family

ID=26312925

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9830577T SI1047665T1 (sl) 1998-01-09 1998-12-23 Inhibitorji matriks-metaloproteaze

Country Status (37)

Country Link
US (1) US6350907B1 (sl)
EP (1) EP1047665B1 (sl)
JP (1) JP3621884B2 (sl)
KR (1) KR100385662B1 (sl)
CN (1) CN1284942A (sl)
AP (1) AP1059A (sl)
AR (1) AR014270A1 (sl)
AT (1) ATE252547T1 (sl)
AU (1) AU736511B2 (sl)
BG (1) BG104575A (sl)
BR (1) BR9813719A (sl)
CA (1) CA2317604C (sl)
CO (1) CO4990971A1 (sl)
CZ (1) CZ20002459A3 (sl)
DE (1) DE69819206T2 (sl)
DK (1) DK1047665T3 (sl)
DZ (1) DZ2701A1 (sl)
EA (1) EA002971B1 (sl)
ES (1) ES2209244T3 (sl)
HN (1) HN1998000199A (sl)
HR (1) HRP20000460A2 (sl)
HU (1) HUP0101300A3 (sl)
IL (1) IL136889A0 (sl)
IS (1) IS5531A (sl)
MA (1) MA26594A1 (sl)
NO (1) NO20003506D0 (sl)
NZ (1) NZ504683A (sl)
OA (1) OA11435A (sl)
PA (1) PA8466101A1 (sl)
PE (1) PE20000176A1 (sl)
PL (1) PL342763A1 (sl)
PT (1) PT1047665E (sl)
SI (1) SI1047665T1 (sl)
SK (1) SK10112000A3 (sl)
TN (1) TNSN99002A1 (sl)
TR (1) TR200001909T2 (sl)
WO (1) WO1999035124A1 (sl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352976B1 (en) 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
EP1140984B1 (en) * 1998-12-31 2003-02-12 Aventis Pharmaceuticals Inc. Selective inhibitors of mmp-12
JP2001055327A (ja) * 1999-06-11 2001-02-27 Fuji Chemical Industries Ltd 新規なヒドロキサム酸誘導体を含む医薬
GB0025310D0 (en) * 2000-10-16 2000-11-29 Pfizer Ltd Process
US6452041B1 (en) 2000-10-16 2002-09-17 Pfizer Inc. Olefination process to itaconate and succinate derivatives
ES2266446T3 (es) * 2001-02-16 2007-03-01 Allelix Neuroscience Inc. Derivados de aminas sustituidas con tiofeno como inhibidores de glyt-1.
GB0126389D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Wafer
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
US20040138103A1 (en) * 2002-11-07 2004-07-15 Procyte Corporation Compositions containing peptide copper complexes and metalloproteinase inhibitors and methods related thereto
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CA2536576C (en) * 2003-08-23 2012-12-18 Vernalis (Oxford) Limited Derivatives of hydroxamic acid as metalloproteinase inhibitors
ES2545688T3 (es) * 2006-09-29 2015-09-15 F. Hoffmann-La Roche Ag Método de evaluación del riesgo de progresión de enfermedad de pacientes con artritis reumatoide
CN104788333B (zh) * 2015-03-19 2017-03-22 中国医科大学 2‑取代‑9,10‑蒽醌类化合物、制备方法及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
US5672583A (en) 1992-11-25 1997-09-30 Merck & Co., Inc. Carboxy-peptidyl derivatives as antidegenerative active agents
GB9308695D0 (en) 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
ATE182137T1 (de) 1993-04-27 1999-07-15 Celltech Therapeutics Ltd Peptidylderivate als inhibitoren von metalloproteinase
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
UA48121C2 (uk) 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
KR100418808B1 (ko) 1994-01-20 2004-07-23 브리티쉬 바이오테크 파마슈티칼스 리미티드 금속단백질분해효소억제제
DE69529100T2 (de) 1994-01-22 2003-07-17 British Biotech Pharm Metalloproteinaseinhibitoren
US6028110A (en) 1994-05-28 2000-02-22 British Biotech Pharmaceuticals Ltd. Succinyl hydroxamic acid, N-formyl-N-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
US5461746A (en) * 1995-01-17 1995-10-31 Tdw Delaware, Inc. Magnetic cleaning pig
GB9507799D0 (en) * 1995-04-18 1995-05-31 British Biotech Pharm Metalloproteinase inhibitors
US5691381A (en) 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
JPH11504934A (ja) 1995-05-10 1999-05-11 カイロサイエンス・リミテッド 金属プロテアーゼとtnfの放出を抑制するペプチジル化合物およびその治療的使用
WO1996035714A1 (en) 1995-05-10 1996-11-14 Chiroscience Limited Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
GB9513331D0 (en) 1995-06-30 1995-09-06 British Biotech Pharm Matrix metalloproteinase inhibitors
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors

Also Published As

Publication number Publication date
KR20010033990A (ko) 2001-04-25
AU736511B2 (en) 2001-07-26
NZ504683A (en) 2002-06-28
BR9813719A (pt) 2000-10-17
PE20000176A1 (es) 2000-03-10
AR014270A1 (es) 2001-02-07
ATE252547T1 (de) 2003-11-15
HUP0101300A2 (hu) 2001-08-28
WO1999035124A1 (en) 1999-07-15
JP3621884B2 (ja) 2005-02-16
CA2317604A1 (en) 1999-07-15
BG104575A (en) 2001-02-28
MA26594A1 (fr) 2004-12-20
US6350907B1 (en) 2002-02-26
IL136889A0 (en) 2001-06-14
JP2002500215A (ja) 2002-01-08
DK1047665T3 (da) 2004-02-02
KR100385662B1 (ko) 2003-05-28
IS5531A (is) 2000-06-13
ES2209244T3 (es) 2004-06-16
EP1047665A1 (en) 2000-11-02
HRP20000460A2 (en) 2001-06-30
TR200001909T2 (tr) 2000-12-21
CA2317604C (en) 2004-12-21
PT1047665E (pt) 2004-01-30
AU2277699A (en) 1999-07-26
NO20003506L (no) 2000-07-07
CN1284942A (zh) 2001-02-21
SK10112000A3 (sk) 2002-02-05
PA8466101A1 (es) 2000-05-24
CO4990971A1 (es) 2000-12-26
OA11435A (en) 2004-04-28
TNSN99002A1 (fr) 2005-11-10
DE69819206D1 (de) 2003-11-27
NO20003506D0 (no) 2000-07-07
CZ20002459A3 (cs) 2001-12-12
AP9901436A0 (en) 1999-03-31
AP1059A (en) 2002-04-22
EP1047665B1 (en) 2003-10-22
EA002971B1 (ru) 2002-12-26
PL342763A1 (en) 2001-07-02
HUP0101300A3 (en) 2002-11-28
EA200000628A1 (ru) 2001-02-26
DZ2701A1 (fr) 2003-09-01
DE69819206T2 (de) 2004-04-15
HN1998000199A (es) 2000-11-03

Similar Documents

Publication Publication Date Title
ZA959948B (en) Matrix metalloprotease inhibitors
GB9912961D0 (en) Metalloprotease inhibitors
PL349192A1 (en) Protease inhibitors
IL150712A0 (en) Matrix metalloproteinase inhibitors
IL138387A0 (en) Enzyme inhibitors
EP1093367A4 (en) PROTEASE INHIBITORS
IL145085A0 (en) Dihetero-substituted metalloprotease inhibitors
AU8858398A (en) Matrix metalloproteinase inhibitors
IL128665A0 (en) Bidenatate metalloprotease inhibitors
ZA96850B (en) Matrix metalloprotease inhibitors.
GB9613547D0 (en) Matrix metalloproteinase inhibitors
HUP0101300A3 (en) Matrix metalloprotease inhibitors
EP1067894A4 (en) PROTHEASEINHIBITOREN
EP1079821A4 (en) PROTEASE INHIBITORS
EP1140897A4 (en) PROTEASE INHIBITORS
EP1086083A4 (en) PROTEASE INHIBITORS
HRP970245B1 (en) Biaryl acetilenes as matrix metalloprotease inhibitors
HUP0302904A3 (en) Matrix metalloproteinase inhibitors
GB9816358D0 (en) Enzyme inhibitors
AU9747098A (en) Aporphinoid matrix metalloproteinase inhibitors
AU2001271068A1 (en) Matrix metalloprotease inhibitors
GB9702085D0 (en) Matrix metalloproteinase inhibitors
SI1060161T1 (sl) Inhibitorji matriksne metaloproteinaze
GB9714548D0 (en) Matrix metalloproteinase inhibitors
HUP9902606A3 (en) Matrix metalloproteinase inhibitors